Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) in the first-line (1L)

被引：0
|
作者：
Paluri, Ravi Kumar
Silver, Michelle
Cockrum, Paul
Dennen, Syvart
机构：
[1] Wake Forest Univ, Winston Salem, NC USA
[2] Genesis Res Grp, Hoboken, NJ USA
[3] Ipsen Biopharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16322
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical outcomes of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Healthcare System
    Patel, Timil
    Srikumar, Thejal
    Miccio, Joseph Anthony
    Lacy, Jill
    Stein, Stacey
    Kortmansky, Jeremy S.
    Staugaard, Carol
    Gambaccini, Melissa
    Axtmayer, Alfredo
    Cecchini, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [42] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
    King, Gentry
    Ittershagen, Stacie
    He, Luyang
    Shen, Ying
    Li, Frank
    Villacorta, Reginald
    ADVANCES IN THERAPY, 2022, 39 (12) : 5433 - 5452
  • [43] Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World
    Gentry King
    Stacie Ittershagen
    Luyang He
    Ying Shen
    Frank Li
    Reginald Villacorta
    Advances in Therapy, 2022, 39 : 5433 - 5452
  • [44] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [45] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [46] Folfirinox (FFX) versus gemcitabine with nab-paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.
    Barrera, Ivan
    Hamalova, Sabina
    Ranger, Jill
    Rho, Henry
    Mamo, Aline
    Batist, Gerald
    Kavan, Petr
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [47] Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO)
    Peixoto, Renata D'Alpino
    Renouf, Daniel John
    Lim, Howard John
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [48] Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs eribulin (Erib) in patients (Pts) with metastatic breast cancer (MBC)
    Parisi, M.
    Gluck, S.
    Pelletier, C.
    Ni, Q.
    Braiteh, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
    Braiteh, Fadi
    Patel, Manish B.
    Parisi, Monika
    Ni, Quanhong
    Park, Siyeon
    Faria, Claudio
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 141 - 148
  • [50] Optimized economic evaluation for the United States (US) of nab-paclitaxel plus gemcitabine (NAB-P plus GEM) FOLFIRINOX (FFX), and gemcitabine (GEM) as first-line treatment for metastatic pancreatic cancer (mPDA)
    Gharaibeh, Mahdi
    McBride, Ali
    Bootman, J. Lyle
    Patel, Hitendra
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345